Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 645 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Diseases Clear all
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye

NCT00799552
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RX-10045, Placebo
Drug
Lead sponsor
Resolvyx Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2010 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Not applicable Interventional Results available

Acute Comfort and Blur of Systane Ultra and Systane

NCT00748865
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Ultra Lubricant Eye Drops, Systane Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 28, 2026, 10:28 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT)

NCT07281950
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
acoltremon 0.003%
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion

NCT04022382
View directory record Official record
Conditions
Dry Eye
Interventions
Restylane Defyne
Device
Lead sponsor
John C Meyer, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 28, 2026, 10:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires

NCT00678860
View directory record Official record
Conditions
Eye Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops

NCT00610480
View directory record Official record
Conditions
Dry Eye Disease
Interventions
1st visit Optive, then 2nd visit Systane, 1st visit Systane, then 2nd visit Optive
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 28, 2026, 10:28 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

NCT02702518
View directory record Official record
Conditions
Ocular Graft vs Host Disease, Dry Eye
Interventions
rhDNase I, Vehicle
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 28, 2026, 10:28 PM EDT
Withdrawn Phase 4 Interventional

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

NCT03398018
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
repository corticotropin injection
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome

NCT03396913
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
IPL, Sham IPL, MGX
Device · Procedure
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Nashville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease

NCT02435914
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
AGN-223575 ophthalmic solution, AGN-223575 vehicle ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
28
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 28, 2026, 10:28 PM EDT
Not listed Phase 4 Interventional

Usability, Immediate, and 30 Day Effect of External Neuromodulation With iTEAR100 Generation 2 in Dry Eye Patients

NCT05304637
View directory record Official record
Conditions
Dry Eye
Interventions
iTEAR100 treatment
Device
Lead sponsor
Olympic Ophthalmics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Issaquah, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Phase 4 Interventional Results available

Effect of Cequa™ in Subjects With Dry Eye Disease

NCT04357795
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CequaTM (Cyclosporine 0.09%) ophthalmic solution
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Fort Myers, Florida • Jacksonville, Florida • Panama City, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 28, 2026, 10:28 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Treating Meibomian Gland Disease in a Pediatric Population

NCT07229001
View directory record Official record
Conditions
Dry Eye Disease, Meibomian Gland Disease
Interventions
Low level light treatment, warm compress and artificial tear
Other
Lead sponsor
Illinois College of Optometry
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 28, 2026, 10:28 PM EDT
Recruiting Phase 4 Interventional

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

NCT06655441
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
3% trehalose
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 28, 2026, 10:28 PM EDT
Not listed Phase 3 Interventional

Study of EBI-005 in Dry Eye Disease (DED)

NCT02405039
View directory record Official record
Conditions
Dry Eye
Interventions
EBI-005, Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 28, 2026, 10:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers

NCT00001953
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dry Eye Assessment and Management: Feasibility Study

NCT01102257
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
Omega-3 EFA Supplement, Olive Oil
Drug
Lead sponsor
Asbell, Penny, M.D.
Individual
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 28, 2026, 10:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Pathogenesis of Idiopathic Dry Eyes

NCT01254201
View directory record Official record
Conditions
Dry Eye, Fibromyalgia
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

NCT03633461
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-02 (simpinicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 28, 2026, 10:28 PM EDT
Completed No phase listed Observational

Effect of Controlled Adverse Environment (CAE) on Tear Film Stability

NCT01547936
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

NCT05062330
View directory record Official record
Conditions
Dry Eye
Interventions
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Raynham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 28, 2026, 10:28 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

NCT02254265
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Disease
Interventions
OTX-101 0.05%, OTX-101 0.09%, Vehicle
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 28, 2026, 10:28 PM EDT
Terminated Not applicable Interventional Results available

Management of Signs and Symptoms Associated With Dry Eye Disease

NCT04015219
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Self retained cryopreserved amniotic membrane, lifitegrast ophthalmic solution
Device · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 28, 2026, 10:28 PM EDT